AAAAAA

   
Results: 1-3 |
Results: 3
BIODISTRIBUTION OF IN-111-LABELED ENGINEERED HUMAN-ANTIBODY CTM01 (HCTM01) IN OVARIAN-CANCER PATIENTS - INFLUENCE OF PRIOR ADMINISTRATION OF UNLABELED HCTM01
Authors: PRINSSEN HM MOLTHOFF CFM VERHEIJEN RHM BROADHEAD TJ KENEMANS P ROOS JC DAVIES Q VANHOF AC FRIER M DENHOLLANDER W WILHELM AJ BAKER TS SOPWITH M SYMONDS EM PERKINS AC
Citation: Hm. Prinssen et al., BIODISTRIBUTION OF IN-111-LABELED ENGINEERED HUMAN-ANTIBODY CTM01 (HCTM01) IN OVARIAN-CANCER PATIENTS - INFLUENCE OF PRIOR ADMINISTRATION OF UNLABELED HCTM01, Cancer immunology and immunotherapy, 47(1), 1998, pp. 39-46
ESCALATING PROTEIN DOSES OF CHIMERIC MONOCLONAL-ANTIBODY MOV18 IMMUNOGLOBULIN-G IN OVARIAN-CARCINOMA PATIENTS - A PHASE-I STUDY
Authors: MOLTHOFF CFM PRINSSEN HM KENEMANS P VANHOF AC DENHOLLANDER W VERHEIJEN RHM
Citation: Cfm. Molthoff et al., ESCALATING PROTEIN DOSES OF CHIMERIC MONOCLONAL-ANTIBODY MOV18 IMMUNOGLOBULIN-G IN OVARIAN-CARCINOMA PATIENTS - A PHASE-I STUDY, Cancer, 80(12), 1997, pp. 2712-2720
LHRH AGONIST TREATMENT OF BREAST-CANCER AND GYNECOLOGICAL MALIGNANCIES - A REVIEW
Authors: BURGER CW PRINSSEN HM KENEMANS P
Citation: Cw. Burger et al., LHRH AGONIST TREATMENT OF BREAST-CANCER AND GYNECOLOGICAL MALIGNANCIES - A REVIEW, European journal of obstetrics, gynecology, and reproductive biology, 67(1), 1996, pp. 27-33
Risultati: 1-3 |